Nama's AI scorecard currently rates BioNTech Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does BNTX report earnings?

BioNTech's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$2.35.

What is the BNTX price target?

The median analyst price target from 20 analysts is $121.55, with a range of $75.63 – $143.49.

Is BNTX Shariah compliant?

Nama's AAOIFI-style screen reads BioNTech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

BioNTech (BNTX)

Healthcare · Biotechnology · NASDAQ

BioNTech (BNTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $21.70B and a free-cash-flow yield of -1.6%. Over the most recent reported fiscal year, revenue grew 4.3%. Nama's AI scorecard rates it Hold, 5.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.0/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -7.8% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-76.6%

How far the last close sits under the highest price of the past five years.

Market cap	$21.70B
Trailing P/E	—
Price / book	1.1
Price / sales	7.4
FCF yield	-1.6%
Dividend yield	—
Gross margin	75.5%
Operating margin	-46.7%
Net margin	-63.6%
Revenue growth (YoY)	+4.3%
Revenue growth (3-yr annual)	-45.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

BNTX earnings

Next report: Mar 2, 2027 (Q4 2026, EPS estimate -$2.35). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$1.76	$0.76	+131.6%	$1.45B
Q2 2026	Aug 4, 2026	-$2.22	-$2.08	-6.7%	$118.47M
Q1 2026	May 5, 2026	-$1.95	-$1.92	-1.6%	$132.49M
Q4 2025	Mar 10, 2026	-$0.33	-$0.25	-32.0%	$1.02B

BNTX analyst price target

Median target $121.55 from 20 analysts, ranging $75.63 – $143.49.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live BNTX data on Nama Insights →

Recent Congressional trades

BioNTech trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Valerie Hoyle	House	Sell	$1,001 - $15,000	Sep 12, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 3, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Sep 11, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	May 15, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Apr 7, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jan 7, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jan 7, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jan 7, 2024

BNTX FAQ

Is BNTX a buy?: Nama's AI scorecard currently rates BioNTech Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BNTX report earnings?: BioNTech's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$2.35.
What is the BNTX price target?: The median analyst price target from 20 analysts is $121.55, with a range of $75.63 – $143.49.
Is BNTX Shariah compliant?: Nama's AAOIFI-style screen reads BioNTech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.